Reid et al. Emphysema, lymphadenopathy, consolidative opacities on CT pre-ICI increase risk of ICI pneumonitis. Pul nodules decrease risk. GERD, asthma in history also increase risk. @RheumNow #ACR22 Abstr#1108 https://t.co/ZD8ibsECnV https://t.co/FVnQgn2I2S

• Abnormal Baseline Chest CT Shows Increased Risk for Immune Checkpoint Inhibitor…

Day 1 Report The masses have returned to #ACR22, a hybrid meeting that began Saturday in Philadelphia. Throngs and gaggles of MSK wannabees crammed the ballrooms and rushed the exhibits as they relived the rheumatologic meeting we once knew. https://t.co/8GjRAT7Zuy https://t.co/vyXRcVxOpo

• https://bit.ly/3Es8fiF

In RA after first-line TNFi, improvements in disease activity & PROs were seen with 2nd line ETN and JAKi. Some measures had greater improvement in JAKi group. Some patients can benefit from TNF cycling. Pappas D CorEvitas Abs1588 https://t.co/cHW5tm97kx #ACR22 @RheumNow https://t.co/bx0p04AQzd

• Outcomes of Etanercept and Janus Kinase Inhibitor Treatment After First-line Us…

Abs 1559 at #ACR22 long-term efficacy of apremilast differs between oral and genital ulcers, skin lesions and joint lesions. There may be differences in the long-term efficacy of apremilast dependent on manifestation type. @RheumNow https://t.co/I8p5fd1CA1 https://t.co/XKjpIUeiah

• Long Term Clinical Effects of Apremilast on Behcet's Disease and Changes i…

In this study by Stoots et al, #lupus pts w/ ⬇️ CV risk (accdg to ASCVD risk calc) had significantly abn. CAC vs. controls and assoc with: 🦋Older age, ⬇️GFR, ⬆️TC&LDL, longer dse duration. More data needed but consider regular CV screens in these pts #ACR22 @RheumNow ABST#1596 https://t.co/pECZw1n6lb

What should you use as a second-line biologic in PsA patients? In pts who discontinued TNFi, switching to a different MOA led to comparable or better outcomes vs. cycling through another TNFi. Abs#1600 @RheumNow #ACR22 https://t.co/9MZPSHD7we

Spangler et al. No increased risk of MI or stroke in denosumab vs zoledronate in 170,000 patients from Optum/MarketScan. @RheumNow #ACR22 Abstr#0575 https://t.co/5fho4WBsIG https://t.co/PNCI4xJ38u

• Myocardial Infarction and Stroke Risks Among Patients Who Initiated Treatment w…

Does curcumin help maintain drug-free remission RA? Answer is No Single center RCT Curcumin vs PBO w/ MTX withdrawal = flare-free survival = median time to flare (219 d vs. 214 d) Serum curcuminoid levels not asso w/ flares https://t.co/3U6W0Iuqrq Abs#1587 #ACR22 @Rheumnow https://t.co/GwAsY7OKTX

• http://bit.ly/3URYakx

Metabolic disorders +diet patterns PsA 👉71.9% obese 👉metabolic synd 46.9% 👉dyslipid 41.9% 👉 HTN 37.5% Diet patterns assoc Dx activity ⬇️sugar⬇️fatigue⬇️PSAID score ⬆️whole fruit ⬇️SJC ⬆️unsat fats ⬆️enthesitis DIPSA -Med/DASH diet PsA ongoing #ACR22 @RheumNow Abst1007 https://t.co/cbggEw6IZp

TOFA and MTX: which one to withdraw first? RCT in 100+ RA pts in remission after 1 yr, 1 yr follow-up Withdraw MTX grp: Remission 30% LDA 40% Withdraw TOFA grp: Remission 50% LDA 65% diff NS small sample 8 SAEs, 72% recovery https://t.co/tMnet32TWF Abs#1586 #ACR22 @Rheumnow https://t.co/PWnkWYdlGk

• Sustained Remission Following the Discontinuation of Tofacitinib in Patients wi…

"Do patients care/look for telehealth in 2022?" Ben Nowell states patients have supported telehealth for access, convenience, and affordability (gas, parking, etc.) 60% of pts still like these visits. Are you doing telemed #ACR22? @RheumNow https://t.co/5fAHsp2kBD

I see more and more studies on #ArtificialIntelligence using social media posts! I think this is an extension/future of qualitative studies 40% of posts associated with negative sentiment toward #pregnancy #SLE fear and sadness! #ACR22 abst#1335 @rheumnow https://t.co/qwk6pYeeXR

• Artificial Intelligence–enabled Sentiment Analysis of Public Attitude Toward Pr…

Cycling to 2nd after 1st line TNFi in AxSpA provides ◦ Limited benefits to pts ◦ Few pts showed clinically meaningful improvement in disease severity after 6 months ◦ Less than 25% pts remained on therapy after 2 years Mease P Abs1499 https://t.co/0Txs82KRbx #ACR22 @RheumNow https://t.co/xJiIWe9yDp

• The Impact of Cycling Among Tumor Necrosis Factor Inhibitors on Disease Control…